SGEN/Takeda Report Data on Adcetris

Zacks

Seattle Genetics, Inc. (SGEN) and partner Takeda Pharmaceuticals (TKPYY) recently reported results from a post-hoc analysis evaluating progression-free survival (PFS) in patients treated with Adcetris.

The post-hoc analysis was conducted on two pivotal phase II studies – one in patients with relapsed or refractory Hodgkin lymphoma (HL) post autologous stem cell transplant (:ASCT) and the other in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

The post-hoc analysis from the phase II study conducted in patients with relapsed or refractory HL post-ASCT showed 62% of the patients achieved a longer PFS with Adcetris as compared with last prior therapy at a median follow-up of 27 months. Median PFS was 9.3 months with Adcetris as compared with 6.1 months in last prior therapy.

Twenty patients went through stem cell transplant (SCT) following Adcetris treatment. It was also noticed that 63% of the patients who relapsed within six months of last ASCT and 65% of the patients who relapsed within twelve months of last ASCT achieved a longer PFS with Adcetris as compared with last prior therapy.

The post-hoc analysis from the phase II study conducted in patients with relapsed or refractory sALCL showed 67% of the patients achieved a longer PFS with Adcetris as compared with last prior therapy at a median follow-up of 22 months. Median PFS was 19.6 months with Adcetris as compared with 5.9 months in last prior therapy. After Adcetris treatment, 20 patients went through SCT.

The data therefore revealed that Adcetris delayed disease progression when compared to prior therapies.

We note that Adcetris was approved by the FDA in Aug 2011 for the treatment of patients with HL after failure of ASCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not suitable for ASCT. Adcetris was also approved for sALCL in treatment-experienced patients. Adcetris generated $33.9 million of revenues in the first quarter of 2013.

Seattle Genetics carries a Zacks Rank #3 (Hold). Right now, Biogen Idec Inc. (BIIB) and Jazz Pharmaceuticals (JAZZ) look more attractive with a Zacks Rank #1 (Strong Buy).

Read the Full Research Report on TKPYY

Read the Full Research Report on SGEN

Read the Full Research Report on BIIB

Read the Full Research Report on JAZZ

Zacks Investment Research



More From Zacks.com

Rates

View Comments (0)